A study finds drusen type is linked to macular atrophy risk in wet AMD, but not to how well eyes respond to anti-VEGF treatment. Medscape Medical News
Category: News
Statins Tied to Lower Risk for Glaucoma, Fewer Procedures
Statin use is associated with a 15% lower risk of developing open-angle glaucoma at 5 years and with lower rates of laser and surgical procedures among patients already diagnosed with the condition. Medscape Medical News
GenSight Biologics et l'Hôpital National des 15-20 annoncent la publication dans le NEJM des résultats de l'essai de Phase 1/2 évaluant GS030 dans la rétinopathie pigmentaire au stade avancé
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour le traitement des m…
Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
GenSight Biologics Reports Cash Position as of September 30, 2026
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
GenSight Biologics publie sa situation de trésorerie au 30 septembre 2026
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurod…
Glaukos Says Late-stage Eye Disease Treatment Shows Lasting Benefits After Single Dose
Glaukos said on Wednesday patients treated with its late-stage eye disease therapy maintained improvements in vision and corneal shape three years after a single treatment… Reuters Health Information
Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today posit…
Staying on Aspirin Seen Mostly Safe in Vitreoretinal Surgery
A meta-analysis finds staying on aspirin therapy did not necessarily raise the risk for ocular bleeding complications during vitreoretinal surgery. Medscape Medical News
Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release thir…
Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced progress in the development of BL1243 (tonabersat), an investigati…
Sightview Debuts New AI Scribe and AI Vision Verify at AAO 2026
TAMPA, Fla.–(BUSINESS WIRE)– #AIScribe–Sightview announced two AI offerings it will showcase at the American Academy of Ophthalmology’s (AAO) 2026 annual meeting, Oct. 9-12 in New Orleans.
Ray Therapeutics Celebrates 2026 Nobel Prize for Foundational Discoveries in Optogenetics
BERKELEY, Calif.–(BUSINESS WIRE)–Ray Therapeutics (RayTx) congratulates Drs. Karl Deisseroth, Peter Hegemann, and Georg Nagel on receiving the 2026 Nobel Prize in Physiology or Medicine for discoveries involving light-gated ion channels that helped l…
Concert Laser Unmasks Eye Condition: EURETINA Case Reports
A laser reveals hidden vascular pathology, ocular findings signal cancer recurrence, and a possible link between eating disorders and retinal hemorrhage. Medscape Medical News
Sling Therapeutics to Present Data from Phase 2b/3 LIDS Trial of Oral IGF-1R Inhibitor Linsitinib in Thyroid Eye Disease at ASOPRS 57th Annual Fall Scientific Symposium
ANN ARBOR, Mich.–(BUSINESS WIRE)–Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced that data from its Phase 2b/3 LI…
Early Pegcetacoplan Use Preserves More Retina in GA
Five-year data show pegcetacoplan slows geographic atrophy, with earlier treatment preserving more retinal tissue than delayed treatment. Medscape Medical News
Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter financial results on Wednesday, Oct. 28, 2026. The …
New 2026 Cell and Gene Therapy Report Charts the Path from Scientific Progress to Patient Access
IRVING, Texas–(BUSINESS WIRE)–InspiroGene™ by McKesson today announced the publication of its third annual 2026 Cell and Gene Therapy Report.
Smartphone 3D Tool May Improve Ptosis Assessment
A smartphone-based 3D tool measures eyelid droop as accurately as specialists and may help clinicians decide which patients need surgery. Medscape Medical News
Retinal Thinning Seen Below Prediabetes A1c Threshold
Retinal neurodegenerative changes were associated with A1c levels below the current threshold for prediabetes, UK Biobank data show. Medscape Medical News